Login to Your Account

NicOx Plunges 21% on FDA Rejection of Arthritis Drug

By Donna Young

Friday, July 23, 2010
Adhering to the advice of a May panel of rheumatologists and drug safety experts, the FDA has refused to approve NicOx SA's experimental osteoarthritis drug naproxcinod until more studies are completed, which sent the French drugmaker's stock into a tailspin Thursday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription